Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

Fig. 1

Proportions of patients < 65 years and ≥ 65 years achieving ACR20, ACR50, and ACR70 responses at weeks 14 (a, b), 24 (c, d), 52 (e, f), and 100 (g, h). Patients in the placebo group could receive golimumab at week 16 if they met the early escape criteria; all other patients in the placebo group crossed over to golimumab at week 24. Treatment group comparisons were not performed after week 24. ACR20/50/70 ≥ 20%/50%/70% improvement in American College of Rheumatology criteria

Back to article page